Neurizon Therapeutics Limited has released a press release.
Motor Neurone Disease Clinical Trial Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Progress update on Phase 1/2 MND interim analysis
- Independent tests show MPL retains long-term shelf-life
- MPL has anti-cancer effects across multiple cancer types
- PharmAust Raises $2.5m via Placement
- MND Trial Successfully Completes Second Patient Cohort
Later from Neurizon Therapeutics
- PharmAust MND Trial Interim Analysis PK Outcomes
- Motor Neurone Disease Phase 1/2 Clinical Trial Update
- MND Biomarkers and Pharmacodynamics Results
- Louie the Beagle surpasses one year on MPL
- Results show MPL suppresses biomarkers associated with MND
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics